Latest Insider Transactions at Cvs Health Corp (CVS)
This section provides a real-time view of insider transactions for Cvs Health Corp (CVS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of CVS HEALTH Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of CVS HEALTH Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 01
2021
|
Karen S Lynch President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
43,211
-45.34%
|
$3,197,614
$74.3 P/Share
|
|
Apr 01
2021
|
Larry J Merlo Director |
SELL
Payment of exercise price or tax liability
|
Direct |
90,351
-6.47%
|
$3,342,987
$37.15 P/Share
|
|
Apr 01
2021
|
Thomas M Moriarty EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
63,445
-26.36%
|
$4,694,930
$74.3 P/Share
|
|
Apr 01
2021
|
Jonathan C Roberts EVP & Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
79,714
-45.17%
|
$5,898,836
$74.3 P/Share
|
|
Mar 31
2021
|
James David Clark SVP, Cont & Chief Acct Officer |
SELL
Open market or private sale
|
Direct |
5,350
-42.48%
|
$406,600
$76.0 P/Share
|
|
Mar 31
2021
|
James David Clark SVP, Cont & Chief Acct Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,350
+29.82%
|
$395,900
$74.29 P/Share
|
|
Mar 29
2021
|
Thomas M Moriarty EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
62,943
-100.0%
|
$4,783,668
$76.15 P/Share
|
|
Mar 29
2021
|
Thomas M Moriarty EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
62,943
+50.0%
|
$4,657,782
$74.29 P/Share
|
|
Mar 26
2021
|
Larry J Merlo Director |
SELL
Open market or private sale
|
Direct |
270,650
-34.06%
|
$20,028,100
$74.73 P/Share
|
|
Mar 26
2021
|
Larry J Merlo Director |
BUY
Exercise of conversion of derivative security
|
Direct |
271,347
+25.45%
|
$20,079,678
$74.29 P/Share
|
|
Mar 26
2021
|
Jonathan C Roberts EVP & Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
73,433
-99.11%
|
$5,434,042
$74.49 P/Share
|
|
Mar 26
2021
|
Jonathan C Roberts EVP & Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
73,433
+49.78%
|
$5,434,042
$74.29 P/Share
|
|
Mar 19
2021
|
Thomas M Moriarty EVP & General Counsel |
SELL
Open market or private sale
|
Indirect |
49,211
-72.97%
|
$3,641,614
$74.15 P/Share
|
|
Mar 16
2021
|
Eva C Boratto EVP & CFO |
SELL
Open market or private sale
|
Direct |
18,882
-20.99%
|
$1,397,268
$74.68 P/Share
|
|
Mar 16
2021
|
Eva C Boratto EVP & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
18,882
+17.35%
|
$1,397,268
$74.29 P/Share
|
|
Mar 02
2021
|
Daniel P Finke EVP/Pres, Health Care Benefits |
SELL
Payment of exercise price or tax liability
|
Direct |
2,413
-13.8%
|
$164,084
$68.94 P/Share
|
|
Feb 28
2021
|
James David Clark SVP, Cont & Chief Acct Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,129
-13.48%
|
$76,772
$68.13 P/Share
|
|
Feb 28
2021
|
Joshua Matthew Flum EVP, ENT STRATEGY & DIGITAL |
SELL
Payment of exercise price or tax liability
|
Direct |
572
-2.18%
|
-
|
|
Feb 26
2021
|
Laurie P. Havanec EVP and Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
44,033
+50.0%
|
$2,994,244
$68.13 P/Share
|
|
Feb 17
2021
|
Edward J Ludwig Director |
BUY
Open market or private purchase
|
Direct |
3,000
+17.31%
|
$216,000
$72.0 P/Share
|
|
Feb 01
2021
|
Lisa Bisaccia Former EVP & Chief HR Officer |
BUY
Grant, award, or other acquisition
|
Direct |
77,457
+43.62%
|
-
|
|
Feb 01
2021
|
Troyen A Brennan EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
94,516
+32.64%
|
-
|
|
Feb 01
2021
|
Eva C Boratto EVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
88,500
+35.67%
|
-
|
|
Feb 01
2021
|
James David Clark SVP, Cont & Chief Acct Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,113
+42.24%
|
-
|
|
Feb 01
2021
|
Daniel P Finke EVP/Pres, Health Care Benefits |
BUY
Grant, award, or other acquisition
|
Direct |
14,280
+37.23%
|
-
|
|
Feb 01
2021
|
Alan Lotvin EVP&President-PharmacyServices |
BUY
Grant, award, or other acquisition
|
Direct |
95,669
+47.88%
|
-
|
|
Feb 01
2021
|
Karen S Lynch President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
95,302
+50.0%
|
-
|
|
Feb 01
2021
|
Larry J Merlo Director |
BUY
Grant, award, or other acquisition
|
Direct |
180,192
+20.39%
|
-
|
|
Feb 01
2021
|
Thomas M Moriarty EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
124,048
+50.0%
|
-
|
|
Feb 01
2021
|
Jonathan C Roberts EVP & Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
175,811
+49.91%
|
-
|
|
Jan 19
2021
|
Larry J Merlo Director |
SELL
Open market or private sale
|
Direct |
62,893
-10.73%
|
$4,842,761
$77.0 P/Share
|
|
Jan 19
2021
|
Larry J Merlo Director |
BUY
Exercise of conversion of derivative security
|
Direct |
64,350
+9.89%
|
$4,761,900
$74.29 P/Share
|
|
Jan 12
2021
|
Lisa Bisaccia Former EVP & Chief HR Officer |
SELL
Open market or private sale
|
Direct |
25,177
-35.08%
|
$1,938,629
$77.0 P/Share
|
|
Jan 12
2021
|
Lisa Bisaccia Former EVP & Chief HR Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,177
+25.97%
|
$1,863,098
$74.29 P/Share
|
|
Jan 08
2021
|
Troyen A Brennan EVP and Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
54,550
+35.17%
|
$4,036,700
$74.29 P/Share
|
|
Jan 08
2021
|
Troyen A Brennan EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
58,896
-56.14%
|
$4,417,200
$75.0 P/Share
|
|
Jan 08
2021
|
Alan Lotvin EVP&President-PharmacyServices |
SELL
Open market or private sale
|
Direct |
25,836
-75.54%
|
$1,937,700
$75.0 P/Share
|
|
Jan 08
2021
|
Alan Lotvin EVP&President-PharmacyServices |
BUY
Exercise of conversion of derivative security
|
Direct |
25,836
+33.43%
|
$1,653,504
$64.24 P/Share
|
|
Dec 02
2020
|
Karen S Lynch President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
12,779
-11.93%
|
$881,751
$69.63 P/Share
|
|
Dec 02
2020
|
Jonathan E. Mayhew EVP - Transformation |
SELL
Payment of exercise price or tax liability
|
Direct |
926
-11.9%
|
$63,894
$69.63 P/Share
|
|
Nov 30
2020
|
Neela Montgomery EVP and Pres., Pharmacy/Retail |
BUY
Grant, award, or other acquisition
|
Direct |
29,502
+50.0%
|
$1,976,634
$67.79 P/Share
|
|
Nov 18
2020
|
C David Brown Ii Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,865
+1.54%
|
$123,090
$66.35 P/Share
|
|
Nov 18
2020
|
Jean Pierre Millon Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,752
+50.0%
|
$115,632
$66.35 P/Share
|
|
Nov 18
2020
|
Tony L White Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,836
+4.98%
|
$121,176
$66.35 P/Share
|
|
Nov 18
2020
|
Mary L Schapiro Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,336
+25.83%
|
$154,176
$66.35 P/Share
|
|
Nov 18
2020
|
David W Dorman Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,408
+3.03%
|
$290,928
$66.35 P/Share
|
|
Nov 18
2020
|
Fernando Aguirre Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,752
+6.91%
|
$115,632
$66.35 P/Share
|
|
Nov 18
2020
|
Nancy Ann Deparle Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,836
+8.18%
|
$121,176
$66.35 P/Share
|
|
Nov 13
2020
|
Alan Lotvin EVP&President-PharmacyServices |
SELL
Open market or private sale
|
Direct |
7,138
-47.08%
|
$499,660
$70.0 P/Share
|
|
Nov 10
2020
|
Joshua Matthew Flum EVP, ENT STRATEGY & DIGITAL |
SELL
Open market or private sale
|
Direct |
21,460
-46.19%
|
$1,502,200
$70.0 P/Share
|